论文部分内容阅读
目的观察派特灵联合重组人干扰素α2b栓治疗老年低度宫颈上皮内瘤变(CIN)的临床疗效及安全性。方法将48例老年低度CIN患者随机分为对照组24例和试验组24例。对照组予以重组人干扰素α2b栓1.0×105U,每2天1次,睡前置于阴道后穹隆;试验组在对照组治疗的基础上,加用派特灵0.5mL,qd,局部湿敷,1个月后改为每2天1次。2组患者均治疗3个月。比较2组患者的临床疗效、血清脂肪细胞因子Chemerin、白细胞介素-10(IL-10)、IL-18水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的有效率分别为83.34%(20/24例)和54.17%(13/24例),差异有统计学意义(P<0.05)。治疗后,试验组和对照血清Chemeri分别为(939.47±104.43),(1204.54±115.34)ng·L~(-1);IL-10分别为(210.47±30.06),(262.45±29.77)pg·mL~(-1);IL-18分别为(181.23±22.34),(235.34±23.17)pg·mL~(-1),差异均有统计学意义(均P<0.05)。试验组的药物不良反应为局部轻微疼痛,对照组的药物不良反应为一过性低热,2组患者的药物不良反应发生率均为4.17%,差异无统计学意义(P>0.05)。结论派特灵联合重组人干扰素α2b栓治疗老年低度CIN的临床疗效显著,其能够显著降低患者的血清Chemerin、IL-10和IL-18水平,且不增加药物不良反应的发生率。
Objective To observe the clinical efficacy and safety of methotrexate combined with recombinant interferon α2b suppository in the treatment of senile low-grade cervical intraepithelial neoplasia (CIN). Methods 48 elderly patients with low CIN were randomly divided into control group (24 cases) and experimental group (24 cases). The control group was given recombinant human interferon α2b suppository 1.0 × 105U, once every 2 days, before going to the vagina and vagina at bedtime; on the basis of the treatment of the control group, the experimental group was treated with peptone 0.5mL, qd, , 1 month later changed to every 2 days 1 time. Two groups of patients were treated for 3 months. The clinical efficacy, serum Chemerin, interleukin-10 (IL-10), IL-18 levels and the incidence of adverse drug reactions were compared between the two groups. Results After treatment, the effective rates of the experimental group and the control group were 83.34% (20/24 cases) and 54.17% (13/24 cases), respectively, the difference was statistically significant (P <0.05). After treatment, the levels of Chemeri in test group and control group were (939.47 ± 104.43) and (1204.54 ± 115.34) ng · L -1, respectively. The levels of IL-10 were (210.47 ± 30.06) and (262.45 ± 29.77) pg · mL ~ (-1) and IL-18 were (181.23 ± 22.34) and (235.34 ± 23.17) pg · mL ~ (-1) respectively, all with statistical significance (all P <0.05). Adverse drug reactions in the experimental group were local minor pain. The adverse drug reaction in the control group was transient hypothermia. The incidence of adverse drug reactions in both groups was 4.17%, with no significant difference (P> 0.05). Conclusions The efficacy of Peitellin combined with recombinant human interferon α2b suppository in the treatment of elderly patients with low CIN is significant. It can significantly reduce the serum Chemerin, IL-10 and IL-18 levels without increasing the incidence of adverse drug reactions.